This mechanism reverses cytarabine-induced Mcl-1/p-Chk1 resistance by targeting the NOXA/Mcl-1/Bim axis, offering a novel triple combination therapy for acute myeloid leukemia (Zhang et al., 2022). Here, CHEK1 is linked to acute myeloid leukemia.